Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.
about
Oligonucleotide therapeutic approaches for Huntington diseasePreclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's diseaseMicroRNA: Implications for Alzheimer Disease and other Human CNS DisordersTherapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer modelMicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic ConsiderationsSubverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic OpportunitiesProgress and Prospects of Anti-HBV Gene Therapy DevelopmentSynthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesNeuronal dark matter: the emerging role of microRNAs in neurodegenerationAdeno-associated virus-mediated microRNA delivery and therapeuticsReinstating aberrant mTORC1 activity in Huntington's disease mice improves disease phenotypes.A non-specific effect associated with conditional transgene expression based on Cre-loxP strategy in miceTargeting mRNA for the treatment of facioscapulohumeral muscular dystrophyChallenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene TherapyCurrent prospects for RNA interference-based therapiesConstruction of permanently inducible miRNA-based expression vectors using site-specific recombinasesEpigenetic mechanisms of neurodegeneration in Huntington's diseaseTargeted delivery of mutant tolerant anti-coxsackievirus artificial microRNAs using folate conjugated bacteriophage Phi29 pRNACharacterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging studyDose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neuronsTargeting several CAG expansion diseases by a single antisense oligonucleotideExpression of multiple artificial microRNAs from a chicken miRNA126-based lentiviral vectorIdentification of allele-specific RNAi effectors targeting genetic forms of Parkinson's diseaseTransfection of small RNAs globally perturbs gene regulation by endogenous microRNAsRNA Interference and Cancer TherapyNalcn Is a "Leak" Sodium Channel That Regulates Excitability of Brainstem Chemosensory Neurons and Breathing.Improved knockdown from artificial microRNAs in an enhanced miR-155 backbone: a designer's guide to potent multi-target RNAiOrganic small hairpin RNAs (OshR): a do-it-yourself platform for transgene-based gene silencing.Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liverTargeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome.Allele-specific RNAi mitigates phenotypic progression in a transgenic model of Alzheimer's disease.Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark periodOmega-1 knockdown in Schistosoma mansoni eggs by lentivirus transduction reduces granuloma size in vivoEffective heritable gene knockdown in zebrafish using synthetic microRNAs.Moderate long-term modulation of neuropeptide Y in hypothalamic arcuate nucleus induces energy balance alterations in adult rats.An artificial miRNA against HPSE suppresses melanoma invasion properties, correlating with a down-regulation of chemokines and MAPK phosphorylation.A construct with fluorescent indicators for conditional expression of miRNA.Heritable and lineage-specific gene knockdown in zebrafish embryoDesign of RNAi hairpins for mutation-specific silencing of ataxin-7 and correction of a SCA7 phenotype.Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
P2860
Q22306293-85D150B8-D453-458A-95CB-39206BD7E768Q24626259-E6D7E4FC-902A-4DFA-BEA0-DE21BF109C2AQ24652987-26B444DD-D958-41D4-858C-626838B62774Q24655262-567E51D8-834B-4C06-99ED-5369E4D8D792Q26773183-758798D2-9446-45EB-9FA9-02BD83BC0FA8Q26784839-F6523D9E-4D5F-4C71-8D1F-7AE6B9E67094Q26799228-C6D00D9B-FE22-478C-80C6-94E08AE57004Q26830610-537FE0FC-7991-4D61-BE7F-CFBBCAB1F984Q26859224-2D179E1D-1DA5-413A-8B30-B54171CEDC4CQ27005597-7430EA01-5CA4-4F87-AE42-97BC84C9CB12Q27306293-439A7BCF-611A-480A-B2BB-BA55FF3F3857Q27347354-3CA30C12-31B8-463F-BBCC-CC0A00158E80Q28069201-546F9CC0-2744-4787-A218-705506D25CBCQ28080450-450D4D4B-B49E-4B2E-BEB7-B45BD8CB5B90Q28235733-282BD827-BABB-42B5-9857-D11A92B6A695Q28253107-FD9B1EA6-8A63-4619-A3CC-338A446E6BE3Q28297936-5BD81251-6F50-498C-B038-2BA663534584Q28478596-009264EB-B96A-40DB-A9E4-DE4D11701259Q28546047-C74A2513-02EE-49F8-B0B4-1442ACF261C1Q28566948-A0D58892-7FBC-4AB6-8762-E690D89D5FCEQ28740870-36105DF3-0011-4E8E-A55E-35274CCF8E35Q28742456-5AAF28A3-46EF-4E52-80F1-26DD7B498CD7Q28743569-4FB5CB31-2763-40AA-BAF0-2E67399EDF37Q28914781-497E6467-6EB1-4A71-8692-F33EC06EBCF9Q29392204-6BC2C33B-5D8E-4D31-BBF5-BF4D592A1334Q30276203-97CB38B6-FD7B-4D31-BA42-B69849AE9F83Q30388048-5D840335-F5AE-44F4-B2D1-5687F56841FBQ30410731-459D9E50-7190-4DA7-B1C9-B9714817DAC0Q30434933-6ED36F71-AD06-4C7E-8139-D4BECF8D736AQ30490193-AE949167-11C8-4648-B123-0E7749C1FF28Q30493543-8BE20220-CE6D-4FE1-AB93-C25E36AE128EQ30498753-85ADA7FA-9E4C-453C-9B3F-4AAFE810AF9FQ30601730-E7EF6172-22A8-407A-9670-23D83858A79DQ30654516-323FFEF1-9A1F-4001-A37E-A13E7BA61EBEQ31027469-1EEE6C02-88FE-45CB-A6EC-46D434F4416FQ31066444-F68BDCEE-9607-4F1B-9E49-DCFCB4E8B7BCQ33374438-1CC71829-D6E4-4320-A6CC-F3BF83EE48F9Q33479155-50FE2E8F-E53F-4DFC-99E6-0D425CDE70ADQ33507519-F360083A-7561-4274-9B33-36CD7E6B043FQ33532273-0DAC0425-1D14-475F-B395-A5DF9EC9B2A5
P2860
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@ast
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@en
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@nl
type
label
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@ast
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@en
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@nl
prefLabel
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@ast
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@en
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@nl
P2093
P2860
P356
P1476
Artificial miRNAs mitigate shR ...... erapeutic development of RNAi.
@en
P2093
Alex Mas Monteys
Barrie J Carter
Barry Polisky
Beverly L Davidson
Brian L Gilmore
Haim Burstein
Inâs Martins
Jodi L McBride
Patrick D Staber
Richard W Peluso
P2860
P304
P356
10.1073/PNAS.0801775105
P407
P577
2008-04-08T00:00:00Z